International Urology Cancer Summit shared an article by Arnab Basu on LinkedIn:
“Advancing Precision Oncology in Metastatic RCC.
New findings highlight the potential of longitudinal ctDNA monitoring as a predictive biomarker for treatment response and progression-free survival in metastatic renal cell carcinoma (RCC).
This study demonstrates high concordance between ctDNA dynamics and clinical outcomes, paving the way for more personalized approaches to therapy and surveillance.
Discover how these insights could impact the future of RCC management.
Read the full study here.”
Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma.
Authors: Arnab Basu, et al.
